

Table A.3 Results of sensitivity analyses for Germany: Incremental cost-effectiveness ratio: cost per quality adjusted life year gained, comparing strategy to no vaccination; price level €2008.

	No immunity				Pre-existing immunity			
	Direct costs		Indirect costs		Direct costs		Indirect costs	
	Early	Late	Early	Late	Early	Late	Early	Late
<i>High vaccine cost</i>								
Whole pop	4481	16587	cs	1957	9910	26611	cs	4742
Elderly	2380	6908	661	5258	8278	15947	6045	13853
High transmitters	2555	13988	cs	4359	2844	12836	cs	cs
<i>No discounting</i>								
Whole pop	1900	8340	cs	cs	4626	13458	cs	cs
Elderly	805	3198	cs	1783	3954	8098	2030	6281
High transmitters	881	6939	cs	cs	952	6283	cs	cs
<i>High transmissibility</i>								
Whole pop	1802	8741	cs	cs	4415	14330	cs	cs
Elderly	668	3057	cs	1722	3542	7619	1676	5864
High transmitters	1203	8951	cs	483	1240	8224	cs	cs
<i>High transmissibility, high cost</i>								
Whole pop	3834	15104	cs	1127	8215	24284	cs	3405
Elderly	1936	5813	544	4478	6578	13165	4712	11411
High transmitters	2841	15425	cs	6958	3023	14264	cs	2218
<i>Low transmissibility</i>								
Whole pop	2818	9895	cs	cs	7178	20223	cs	cs
Elderly	1357	4257	cs	2148	6290	13078	3507	10505
High transmitters	837	6295	cs	cs	994	7522	cs	cs
<i>Low transmissibility, high cost</i>								
Whole pop	5490	16985	cs	1550	12716	33877	cs	11193
Elderly	3060	7766	867	5657	11042	22021	8259	19448
High transmitters	2258	11120	cs	59	2648	13178	cs	cs
<i>Low vaccine coverage</i>								
Whole pop	2874	15110	cs	605	5455	22067	cs	672
Elderly	2931	8110	1262	6480	9375	17107	7291	15222
High transmitters	3274	15715	cs	6226	3443	12713	cs	82
<i>High pre-existing immunity</i>								
Whole pop	NA	NA	NA	NA	8860	34403	cs	7740
Elderly	NA	NA	NA	NA	23289	37947	21351	36380
High transmitters	NA	NA	NA	NA	4076	15333	cs	cs

Note: Bold figures indicates most cost-effective strategy; NA: Not applicable; cs=cost saving.

Table A.4 Results of sensitivity analyses for the Netherlands: Incremental cost-effectiveness ratio: cost per quality adjusted life year gained, comparing strategy to no vaccination; price level €2008.

	No immunity				Pre-existing immunity			
	Direct costs		Indirect costs		Direct costs		Indirect costs	
	Early	Late	Early	Late	Early	Late	Early	Late
<i>High vaccine cost</i>								
Whole pop	5229	17374	cs	cs	10972	30538	cs	cs
Elderly	2598	6576	cs	3603	9330	18547	5389	14625
High transmitters	1765	15736	cs	491	1660	17732	cs	cs
<i>No discounting</i>								
Whole pop	2514	9590	cs	cs	5639	16913	cs	cs
Elderly	1122	3448	cs	622	5038	10417	1297	6696
High transmitters	493	8528	cs	cs	308	9439	cs	cs
<i>High transmissibility</i>								
Whole pop	2179	8957	cs	cs	4856	15261	cs	cs
Elderly	881	2907	cs	464	4049	8327	666	4962
High transmitters	719	10493	cs	cs	549	11561	cs	cs
<i>High transmissibility, high cost</i>								
Whole pop	4432	15429	cs	cs	8992	25867	cs	cs
Elderly	2107	5400	cs	2957	7278	14233	3895	10867
High transmitters	2080	17981	cs	4412	2008	19912	cs	cs
<i>Low transmissibility</i>								
Whole pop	3445	11557	cs	cs	8086	22765	cs	cs
Elderly	1654	4581	cs	882	7412	15431	2766	10805
High transmitters	317	7434	cs	cs	53	9246	cs	cs
<i>Low transmissibility, high cost</i>								
Whole pop	6502	19672	cs	cs	14263	38097	cs	2814
Elderly	3373	8132	cs	4433	12759	25792	8113	21166
High transmitters	1427	13004	cs	cs	1212	16162	cs	cs
<i>Low vaccine coverage</i>								
Whole pop	3228	15035	cs	cs	6490	24299	cs	cs
Elderly	3086	7170	37	3951	12032	23434	10537	23852
High transmitters	2209	14665	cs	566	2408	18090	cs	cs
<i>High pre-existing immunity</i>								
Whole pop	NA	NA	NA	NA	9020	34843	cs	cs
Elderly	NA	NA	NA	NA	32057	59097	28259	55288
High transmitters	NA	NA	NA	NA	2525	19239	cs	cs

Note: Bold figures indicates most cost-effective strategy; NA: Not applicable; cs=cost saving.

Table A.5 Results of sensitivity analyses for the United Kingdom: Incremental cost-effectiveness ratio: cost per quality adjusted life year gained, comparing strategy to no vaccination; price level €2008.

	No immunity				Pre-existing immunity			
	Direct costs		Indirect costs		Direct costs		Indirect costs	
	Early	Late	Early	Late	Early	Late	Early	Late
<i>High vaccine cost</i>								
Whole pop	4394	15761	cs	5521	9195	25769	cs	10734
Elderly	2252	5960	1042	4790	7231	14417	5711	12913
High transmitters	1243	11971	cs	5080	2408	13115	cs	2059
<i>No discounting</i>								
Whole pop	1844	7938	cs	cs	4153	12877	cs	89
Elderly	892	2876	cs	1860	3523	7345	2209	6045
High transmitters	141	5838	cs	cs	479	6114	cs	cs
<i>High transmissibility</i>								
Whole pop	1705	9362	cs	cs	3893	13878	cs	cs
Elderly	773	3055	cs	2120	3093	6851	1830	5604
High transmitters	326	9311	cs	3267	819	9111	cs	cs
<i>High transmissibility, high cost</i>								
Whole pop	3739	16356	cs	6452	7601	23984	cs	9297
Elderly	1870	5688	869	4724	5782	12082	4479	10794
High transmitters	1521	16308	cs	10188	2932	16262	cs	6179
<i>Low transmissibility</i>								
Whole pop	2755	9777	cs	cs	6496	18838	cs	3557
Elderly	1386	3885	cs	2431	5515	11653	3692	9849
High transmitters	cs	5243	cs	cs	cs	6841	cs	cs
<i>Low transmissibility, high cost</i>								
Whole pop	5425	16807	cs	6274	11803	31815	cs	16533
Elderly	2843	6900	1342	5446	9582	19555	7759	17752
High transmitters	953	9508	cs	1765	1569	12408	cs	324
<i>Low vaccine coverage</i>								
Whole pop	2546	16381	cs	6232	5655	21769	cs	6763
Elderly	2787	7974	1607	6827	8762	17281	7259	15785
High transmitters	1890	15724	cs	9043	3448	14183	cs	3193
<i>High pre-existing immunity</i>								
Whole pop	NA	NA	NA	NA	7672	31737	cs	13143
Elderly	NA	NA	NA	NA	23435	44397	21879	42845
High transmitters	NA	NA	NA	NA	3413	16120	cs	2782

Note: Bold figures indicates most cost-effective strategy; NA: Not applicable; cs=cost saving.